Shortly after her mother was diagnosed with breast cancer in early 2013, Stacey Tinianov went in for her first mammogram. Several days and one biopsy later, she got a phone call that said she, too, had breast cancer.
“I went from my very first mammogram to, ‘you need to have a mastectomy,’ in two weeks,” Stacey said. “And what I was missing were options. I was missing options with context.” Continue reading…
In a recent video podcast, Cancer Commons board member Dr. Larry Marton discusses quality assurance in the context of personalized medicine. Dr. Marton is heavily involved at Cancer Commons; he tells our story at the 32:00 mark. From Mendelspod, makers of the podcast:
“Larry’s core message is that we must improve the quality of new clinical tests which have been translated from research. It is the key to demonstrating clinical relevance, he says. There are issues with sampling, with analytics, and with compliance. What can those in the industry do to better the quality assurance? And how can the industry better engage the medical community? A veteran shares his insights.”